க்னொபப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from க்னொபப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In க்னொபப் Today - Breaking & Trending Today
(0) Poster presentation will describe effects of dexpramipexole on blood absolute eosinophil count, lung function, and safety Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference. We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma, said Michael Bozik, M.D., president and CEO of Knopp. Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm. ....
Knopp Biosciences LLC: Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma Reduction in blood eosinophil count correlated with clinically important improvement in lung function Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The EXHALE study met its primary endpoint, with dexpramipexole demonstrating a statistically significant, dose-dependent reduction in blood absolute eosinophil count (AEC) from Baseline to Week 12 compared to placebo when added to standard of care. The magnitude of change in blood AEC was consistent with the eosinophil depletion seen in previous clinical trials of dexpramipexole in other indications. ....